UH-232
Prijeđi na navigaciju
Prijeđi na pretragu
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| cis-5-hidroksi-1-metil-2-(N,N-propilamino)tetralin | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 95999-12-5 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 123696 | ||
| Hemijski podaci | |||
| Formula | C18H29NO | ||
| Mol. masa | 275,428 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
UH-232 ((+)-UH232) je lek koji deluje mešoviti agonist-antagonist dopaminskih receptora koji je selektivan za pojedine podtipove. On je slab parcijalni agonist na D3 podtipu,[3] i antagonist na D2Sh autoreceptorima u dopaminergičnim nervnim završecima.[4][5] On uzrokuje otpuštanje dopamina u mozgu i ima stimulišuče dejstvo.[6][7][8] On sprečava načina ponašanja koji je uzrokovan kokainom.[9] On je ispitivan za primenu u lečenju šizofrenije. Ispitivanja su prekinuta jer je pogoršavao simptome.[10]
Reference[uredi | uredi kod]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Griffon N, Pilon C, Schwartz JC, Sokoloff P (1995). „The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist”. European journal of pharmacology 282 (1–3): R3–4. DOI:10.1016/0014-2999(95)00460-3. PMID 7498261.
- ↑ Waters N, Lagerkvist S, Löfberg L, Piercey M, Carlsson A (1993). „The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study”. European journal of pharmacology 242 (2): 151–63. DOI:10.1016/0014-2999(93)90075-S. PMID 8253112.
- ↑ Aretha, CW; Sinha, A; Galloway, MP (1995). „Dopamine D3-preferring ligands act at synthesis modulating autoreceptors”. The Journal of pharmacology and experimental therapeutics 274 (2): 609–13. PMID 7636720.
- ↑ Waters, N; Hansson, L; Löfberg, L; Carlsson, A (1994). „Intracerebral infusion of (+)-AJ76 and (+)-UH232: effects on dopamine release and metabolism in vivo”. European journal of pharmacology 251 (2–3): 181–90. DOI:10.1016/0014-2999(94)90399-9. PMID 8149975.
- ↑ Sotnikova, TD; Gainetdinov, RR; Grekhova, TV; Rayevsky, KS (2001). „Effects of intrastriatal infusion of D2 and D3 dopamine receptor preferring antagonists on dopamine release in rat dorsal striatum (in vivo microdialysis study)”. Pharmacological research : the official journal of the Italian Pharmacological Society 43 (3): 283–90. DOI:10.1006/phrs.2000.0773. PMID 11401421.
- ↑ Millan, MJ; Seguin, L; Gobert, A; Cussac, D; Brocco, M (2004). „The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats”. Psychopharmacology 174 (3): 341–57. DOI:10.1007/s00213-003-1770-x. PMID 14985929.
- ↑ Piercey, MF; Lum, JT; Hoffmann, WE; Carlsson, A; Ljung, E; Svensson, K (1992). „Antagonism of cocaine's pharmacological effects by the stimulant dopaminergic antagonists, (+)-AJ76 and (+)-UH232”. Brain research 588 (2): 217–22. DOI:10.1016/0006-8993(92)91578-3. PMID 1393576.
- ↑ Lahti, AC; Weiler, M; Carlsson, A; Tamminga, CA (1998). „Effects of the D3 and autoreceptor-preferring dopamine antagonist (+)-UH232 in schizophrenia”. Journal of neural transmission (Vienna, Austria : 1996) 105 (6–7): 719–34. DOI:10.1007/s007020050091. PMID 9826114.
